News

Video

Monitoring Patients With HER2+ mBC After Discontinuing Trastuzumab Deruxtecan

Author(s):

Jane L. Meisel, MD

Jane Meisel, MD, delves into considerations around discontinuing trastuzumab deruxtecan for the treatment of HER2+ metastatic breast cancer, explaining that therapy may be halted due to disease progression or toxicity, and the importance of monitoring patients with regular scans.

Related Videos
Ruth M. O’Regan, MD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Sheldon M. Feldman, MD
Dana Zakalik, MD
Alberto Montero, MD, MBA, CPHQ
Jairam Krishnamurthy, MD, FACP
Deena Mary Atieh Graham, MD
Sheldon M. Feldman, MD
Sheldon M. Feldman, MD
In this episode of OncChats: Empowering Community Cancer Care, Dr. Rai emphasizes the importance of community outreach and support for patients with cancer, highlighting the need for holistic care that addresses both physiological and psychological aspects of treatment while reinforcing the value of strong relationships between primary care physicians and specialists.
Related Content
Jairam Krishnamurthy, MD, FACP
November 22nd 2024

Category 1 Recommendation of Ribociclib Plus an AI Represents Huge Advancement in Breast Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

Lubna Naaz Chaudhary, MD, MS, associate professor, medicine, Medical College of Wisconsin
November 19th 2024

Ongoing and Planned Research Build on Prior Advancements in ER+/HER2– Breast Cancer

MedNews Week
September 4th 2024

Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer

Kari Wisinski, MD, the Endowed Professor of Hematology and Oncology and chief of the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine at the University of Wisconsin School of Medicine and Public Health in Madison
November 12th 2024

Genomic Predictors Inform the Evolving Role of Chemotherapy in Breast Cancer Management

BT7480 in Nectin-4+, CD137+ Tumors | Image Credit: © Katsyarina - stock.adobe.com
November 7th 2024

BT7480 Shows Preliminary Activity in Nectin-4+, CD137+ Tumors